Literature DB >> 19965854

FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis.

Ian P Blair1, Kelly L Williams, Sadaf T Warraich, Jennifer C Durnall, Annora D Thoeng, Jim Manavis, Peter C Blumbergs, Steve Vucic, Matthew C Kiernan, Garth A Nicholson.   

Abstract

OBJECTIVE: FUS gene mutations were recently identified in familial amyotrophic lateral sclerosis (ALS). The present studies sought to define the clinical, post-mortem and neurophysiological phenotypes in ALS families with FUS mutations and to determine the frequency of FUS mutations in familial and sporadic ALS.
METHODS: FUS was screened for mutations in familial and sporadic ALS cases. Clinical, post-mortem and neurophysiological features of large families with FUS mutations are described. RESULTS AND
CONCLUSIONS: FUS mutations were evident in 3.2% (4/124) of familial ALS, representing the second most common gene abnormality to be described in familial ALS after SOD1. No mutations were present in 247 sporadic ALS cases. The clinical presentation in 49 affected patients was consistent with a predominantly lower motor neuron disorder, supported by post-mortem findings. Upper motor neuron involvement varied, with Wallerian degeneration of corticospinal tracts present in one post-mortem case but absent in a second case from the same family. Features of cortical hyperexcitability demonstrated upper motor neuron involvement consistent with other forms of familial and sporadic ALS. One case presented with frontotemporal dementia (FTD) indicating that this may be a rare presenting feature in families with FUS mutation. Ubiquitin-positive cytoplasmic skein-like inclusions were present in lower motor neurons, but in contrast to sporadic ALS, no TDP-43 pathology was evident. Mutation-specific clinical features were identified. Patients with a R521C mutation were significantly more likely to develop disease at a younger age, and dropped-head syndrome was a frequent feature. Reduced disease penetrance was evident among most affected families.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965854     DOI: 10.1136/jnnp.2009.194399

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  86 in total

1.  De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis.

Authors:  Mariely DeJesus-Hernandez; Jannet Kocerha; NiCole Finch; Richard Crook; Matt Baker; Pamela Desaro; Amelia Johnston; Nicola Rutherford; Aleksandra Wojtas; Kathleen Kennelly; Zbigniew K Wszolek; Neill Graff-Radford; Kevin Boylan; Rosa Rademakers
Journal:  Hum Mutat       Date:  2010-05       Impact factor: 4.878

2.  Lower motor neuron disease caused by a novel FUS/TLS gene frameshift mutation.

Authors:  Makoto Hara; Masayuki Minami; Satoshi Kamei; Naoki Suzuki; Masaaki Kato; Masashi Aoki
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

Review 3.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

Review 4.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

5.  Combined FDG and raclopride PET study in a case of ALS with the R521C FUS gene mutation.

Authors:  Satoshi Kono; Yasuomi Ouchi; Tatsuhiro Terada; Makiko Suzuki; Shunsuke Yagi; Hiroaki Miyajima
Journal:  J Neurol       Date:  2011-07-15       Impact factor: 4.849

6.  Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation.

Authors:  Ian R A Mackenzie; Olaf Ansorge; Michael Strong; Juan Bilbao; Lorne Zinman; Lee-Cyn Ang; Matt Baker; Heather Stewart; Andrew Eisen; Rosa Rademakers; Manuela Neumann
Journal:  Acta Neuropathol       Date:  2011-05-21       Impact factor: 17.088

Review 7.  Impairments in Motor Neurons, Interneurons and Astrocytes Contribute to Hyperexcitability in ALS: Underlying Mechanisms and Paths to Therapy.

Authors:  Dzung Do-Ha; Yossi Buskila; Lezanne Ooi
Journal:  Mol Neurobiol       Date:  2017-02-03       Impact factor: 5.590

Review 8.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

9.  Sustained expression of TDP-43 and FUS in motor neurons in rodent's lifetime.

Authors:  Cao Huang; Pedro Yuxing Xia; Hongxia Zhou
Journal:  Int J Biol Sci       Date:  2010-07-04       Impact factor: 6.580

Review 10.  Inflammatory mediators as biomarkers in brain disorders.

Authors:  Domenico Nuzzo; Pasquale Picone; Luca Caruana; Sonya Vasto; Annalisa Barera; Calogero Caruso; Marta Di Carlo
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.